keyword
Keywords treatment hemoglobin prostate ...

treatment hemoglobin prostate cancer

https://read.qxmd.com/read/38489926/compliance-with-nccn-guidelines-for-evaluation-and-treatment-of-anemia-among-patients-with-solid-tumors
#1
JOURNAL ARTICLE
Demetra Hypatia Hufnagel, Lia Manfredi Bos, Alaina Johnson Brown, Lauren Shore Prescott
BACKGROUND: NCCN Guidelines for Hematopoietic Growth Factors recommend evaluation and treatment of anemia in patients with cancer. However, a paucity of data exists regarding compliance with these recommendations. METHODS: A retrospective cohort study was performed of patients diagnosed with any solid tumor at Vanderbilt University Medical Center from 2008 to 2017. Tumor registry-confirmed cancer cases were identified by ICD-O codes using the Synthetic Derivative database...
March 15, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38447942/-role-of-bone-scan-index-bsi-in-the-prognosis-and-treatment-efficacy-in-castration-sensitive-prostate-cancer-patients-with-bone-metastasis
#2
JOURNAL ARTICLE
Kaho Deguchi, Takeshi Sasaki, Hiroyuki Oue, Takashi Okamoto, Momoko Kato, Shinya Kajiwara, Shinichiro Higashi, Satoru Masui, Kouhei Nishikawa, Takahiro Inoue
Bone is the most common metastatic site in prostate cancer (PCa). Although the extent of disease (EOD) grade is used for evaluating burden of bone metastasis, the accuracy of bone metastasis classification needs improvement. Bone scan index (BSI) was developed as a quantitative tool to enhance the interpretability and clinical relevance of the bone scan. This study aimed to explore the role of BSI using BONENAVI® software in determining the prognosis and treatment efficacy in castration-sensitive PCa (mCSPC) patients with bone metastasis...
February 2024: Hinyokika Kiyo. Acta Urologica Japonica
https://read.qxmd.com/read/38398163/the-detection-and-negative-reversion-of-circulating-tumor-cells-as-prognostic-biomarkers-for-metastatic-castration-resistant-prostate-cancer-with-bone-metastases-treated-by-enzalutamide
#3
JOURNAL ARTICLE
So Nakamura, Masayoshi Nagata, Naoya Nagaya, Takeshi Ashizawa, Hisashi Hirano, Yan Lu, Hisamitsu Ide, Shigeo Horie
Enzalutamide is a second-generation androgen receptor inhibitor that increases overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the efficacy of circulating tumor cell (CTC) status as a prognostic biomarker following enzalutamide administration. A retrospective subgroup analysis and prognostic survey were conducted on 43 patients with mCRPC and bone metastases treated in Juntendo University-affiliated hospitals from 2015 to 2022. Patients were treated with 160 mg enzalutamide daily...
February 13, 2024: Cancers
https://read.qxmd.com/read/38158645/biochemical-progression-free-and-overall-survival-among-black-men-with-stage-iv-prostate-cancer-in-south-africa-results-from-a-prospective-cohort-study
#4
JOURNAL ARTICLE
Yoanna S Pumpalova, Adarsh Ramakrishnan, Michael May, Audrey Pentz, Shauli Minkowitz, Sean Doherty, Elvira Singh, Wenlong Carl Chen, Timothy R Rebbeck, Alfred I Neugut, Maureen Joffe
BACKGROUND: Men of African descent are disproportionately affected by prostate cancer (PCa), and many have metastatic disease at presentation. In South Africa (SA), androgen deprivation therapy (ADT) is the first-line treatment for stage IV PCa. OBJECTIVE: To identify predictors of overall survival (OS) in Black South African men with stage IV PCa treated with ADT. DESIGN, SETTING, AND PARTICIPANTS: Men diagnosed with prostate cancer (3/22/2016-10/30/2020) at Chris Hani Baragwanath Academic Hospital in Soweto, Johannesburg, were recruited for the Men of African Descent with Cancer of the Prostate study...
December 29, 2023: Cancer Medicine
https://read.qxmd.com/read/38135185/a-potential-biomarker-of-radiosensitivity-in-metastatic-hormone-sensitive-prostate-cancer-patients-treated-with-combination-external-beam-radiotherapy-and-radium-223
#5
JOURNAL ARTICLE
K M Redmond, P G Turner, A Cole, S Jain, K M Prise, J M O'Sullivan
PURPOSE: The ADRRAD trial reported the safety and feasibility of the combination of external beam radiotherapy and radium-223 in the treatment of de novo bone metastatic prostate. This study aimed to determine if any biomarkers predictive of response to these treatments could be identified. EXPERIMENTAL DESIGN: 30 patients with newly diagnosed bone metastatic hormone sensitive prostate cancer were recruited to the ADRRAD trial. Blood samples were taken pre-treatment, before cycles 2 to 6 of radium-223, and 8 weeks and 6 months after treatment...
December 20, 2023: Radiotherapy and Oncology
https://read.qxmd.com/read/38027014/indication-and-adverse-event-profiles-of-denosumab-and-zoledronic-acid-based-on-u-s-fda-adverse-event-reporting-system-faers
#6
JOURNAL ARTICLE
Si Su, Liuqing Wu, Guibao Zhou, Lingling Peng, Huanzhe Zhao, Xiao Wang, Kuan Li
Objective: To investigate adverse events (AEs) associated with denosumab (Dmab) and zoledronic acid (ZA), compare their association strengths, and explore potential applications to provide clinical reference. Methods: We collected data from FAERS from January 2004 to November 2022 and mined AE signals for Dmab and ZA using ROR values. We compared signal intensity for same AEs and investigated off-label use. We also examined their AEs in adjuvant therapy for breast and prostate cancer. Results: 154,735 reports of primary suspect drugs were analyzed in the FAERS database (Dmab: 117,857; ZA: 36,878)...
2023: Frontiers in Pharmacology
https://read.qxmd.com/read/37909677/effect-of-bmi-and-hemoglobin-a1c-on-survival-of-veterans-with-metastatic-castration-resistant-prostate-cancer-treated-with-abiraterone-or-enzalutamide
#7
JOURNAL ARTICLE
Srinivas Govindan, Nina Cheranda, Forest Riekhof, Suhong Luo, Martin W Schoen
BACKGROUND: Abiraterone acetate and enzalutamide are two common therapies for metastatic castration-resistant prostate cancer (mCRPC) that have shown improved overall survival (OS). The drugs have different mechanisms of action with limited comparative trials to evaluate treatment in patients with comorbidities such as obesity and diabetes. This is important since abiraterone requires the co-administration of prednisone. We assessed the relationship between body mass index (BMI), hemoglobin A1c (HbA1c), treatment, and survival in mCRPC...
November 1, 2023: Prostate
https://read.qxmd.com/read/37894274/prognostic-value-of-the-de-ritis-ratio-for-overall-survival-in-patients-with-metastatic-castration-resistant-prostate-cancer-undergoing-177-lu-lu-psma-617-radioligand-therapy
#8
JOURNAL ARTICLE
Sebastian Gaal, Kai Huang, Julian M M Rogasch, Hans V Jochens, Maria De Santis, Barbara Erber, Holger Amthauer
The De Ritis ratio (=aspartate transaminase/alanine transaminase) has shown prognostic value in different cancer types. This is the first such analysis in prostate cancer patients undergoing radioligand therapy (RLT) with [177 Lu]Lu-PSMA-617. This retrospective monocentric analysis included 91 patients with a median of 3 RLT cycles (range 1-6) and median cumulative activity of 17.3 GBq. Univariable Cox regression regarding overall survival (OS) included age, different types of previous treatment, metastatic patterns and different laboratory parameters before RLT...
October 10, 2023: Cancers
https://read.qxmd.com/read/37846828/-transurethral-plasma-resection-of-the-prostate-for-acute-urinary-retention-in-patients-with-advanced-prostate-cancer
#9
JOURNAL ARTICLE
Kun Pang, Qing Liang, Bo Chen, Zhen-Duo Shi, Yang Dong, Cong-Hui Han
OBJECTIVE: To compare the safety of transurethral plasma resection of the prostate (TuPkRP) in the treatment of advanced PCa (APC)-related acute urinary retention (AUR) with that in the treatment of BPH-related AUR and investigate the oncologic characteristics of the PCa patient after TuPkRP. METHODS: In this retrospective study, we first compared the baseline data between the patients with APC-related AUR (group A, n = 32) and those with BPH-related AUR (group B, n = 45) as well as their surgical parameters, such as the operation time, pre- and post-operative hemoglobin levels, IPSS at 3 months after TuPkRP and length of postoperative hospital stay...
January 2023: Zhonghua Nan Ke Xue, National Journal of Andrology
https://read.qxmd.com/read/37686668/prognostic-role-of-dynamic-changes-in-serological-markers-in-metastatic-hormone-na%C3%A3-ve-prostate-cancer
#10
JOURNAL ARTICLE
Soumyajit Roy, Yilun Sun, Christopher J D Wallis, Amar U Kishan, Scott C Morgan, Daniel E Spratt, Shawn Malone, Fred Saad
We investigated whether inter-patient variation in the dynamic trajectory of hemoglobin (Hb), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), and prostate-specific antigen (PSA) can prognosticate overall survival (OS) in de novo mHSPC. This is a secondary analysis of the LATITUDE trial in which high-risk de novo mHSPC patients were randomly assigned to receive either androgen deprivation therapy (ADT) plus abiraterone or ADT plus placebo. We used a five-fold cross-validated joint model approach to determine the association of temporal changes in the serological markers with OS...
September 2, 2023: Cancers
https://read.qxmd.com/read/37596454/simultaneous-thulium-laser-resection-of-the-prostate-and-transperineal-prostate-biopsy-in-clinically-diagnosed-metastatic-prostate-cancer-with-bladder-outlet-obstruction
#11
JOURNAL ARTICLE
Youwei Shi, Tianyu Cao, Junhao Xu, Di Cui, Xiaohai Wang, Yiping Zhu, Yuan Ruan, Bangmin Han, Shujie Xia, Yuee Chen, Wenhuan Guo, Yifeng Jing
Metastatic prostate cancer (mPCa) patients complicated with bladder outlet obstruction (BOO) are often referred to a urologist. Androgen deprivation therapy (ADT) combined with indwelling catheter usually be the initial management. To retrospectively analysis the safety and efficacy of simultaneous thulium laser resection of the prostate (TmLRP) and transperineal prostate biopsy in metastatic prostate cancer with bladder outlet obstruction. From January 2016 to December 2021, 67 clinically diagnosed mPCa with BOO patients were included in this study...
August 18, 2023: Lasers in Medical Science
https://read.qxmd.com/read/37589478/development-and-validation-of-a-nomogram-for-predicting-osteoporosis-in-prostate-cancer-patients-a-cross-sectional-study-from-china
#12
JOURNAL ARTICLE
Shangrong Wu, Xudong Ma, Zhengxin Liang, Yuchen Jiang, Shuaiqi Chen, Guangyu Sun, Kaifei Chen, Ranlu Liu
BACKGROUND: The specific risk factors contributing to the development of osteoporosis and the appropriate timing of treatment in Chinese prostate cancer (PCa) patients remain unclear. Our objective was to develop and validate a nomogram capable of predicting the occurrence of osteoporosis in PCa patients. METHODS: We conducted a cross-sectional study with PCa patients attending the Second Hospital of Tianjin Medical University, collecting data from June 2021 to February 2023...
August 17, 2023: Prostate
https://read.qxmd.com/read/37440195/therapeutic-efficacy-and-safety-results-of-177lu-psma-therapy-in-metastatic-castration-resistant-prostate-cancer-patients-first-experience-of-a-developing-south-asian-country
#13
JOURNAL ARTICLE
Azra Parveen, Arzoo Fatima, Ismat Fatima, Irfan U Khan, Abubaker Shahid
OBJECTIVE: Metastatic castration resistant-prostate cancer (mCRPC) is deadly condition that remains incurable despite various therapies. Initial studies have shown promising results with Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA) therapy for advanced prostate cancer. However, most of the published efficacy and safety data is retrospective. The purpose of the study was to prospectively evaluate the therapeutic efficacy and safety results of 177Lu-PSMA therapy in mCRPC patients after 2 cycles...
July 14, 2023: Nuclear Medicine Communications
https://read.qxmd.com/read/37419250/prognostic-biomarkers-in-the-use-of-223-radium-in-patients-with-metastatic-castration-resistent-prostate-cancer
#14
JOURNAL ARTICLE
Mónica Vidal, Rodrigo Cárdenas-Perilla, Alejandro Delgado, Sarai Morón, Juan Luis Londoño Blair, Iván Vega, Jose Jaime Correa Ochoa, Julián Rojas
OBJECTIVES: This study aimed to establish basal biomarkers in patients with bone metastatic castration-resistant prostate cancer (mCRPC) treated with 223 Ra to predict better overall survival (OS), and assess hematologic toxicity and treatment response. MATERIALS AND METHODS: This was a retrospective multicenter study including 151 patients with mCRPC between 2013-2020. OS was assessed according to basal hemoglobin (Hb), prostate-specific antigen (PSA), and alkaline phosphatase (AP) values, the World Health Organization pain scale, the Eastern Cooperative Oncology Group (ECOG) performance status scale, the number of metastatic lesions on bone scintigraphy (BS), and the use of protective bone agents and the dose received...
July 5, 2023: Revista española de medicina nuclear e imagen molecular
https://read.qxmd.com/read/37403908/lutetium-177-prostate-specific-membrane-antigen-617-treatment-in-metastatic-castration-resistant-prostate-adenocarcinoma-results-of-single-center-experience
#15
JOURNAL ARTICLE
Adem Maman
OBJECTIVE: Lutetium-177 prostate-specific membrane antigen-617 is a novel alternative therapeutic option in metastatic castration-resistant prostate cancer, especially useful for patients who do not respond to standard therapy methods. The aim of this study was to define the efficacy and safety profile of lutetium-177 prostate- specific membrane antigen-617 treatment in a group of patients with metastatic castration-resistant prostate cancer. MATERIALS AND METHODS: Study group included 34 men with metastatic castration-resistant prostate cancer (median, 69...
June 2023: Eurasian Journal of Medicine
https://read.qxmd.com/read/37385221/tumor-volume-on-psma-pet-as-a-prognostic-biomarker-in-prostate-cancer-patients-treated-with-cabazitaxel
#16
JOURNAL ARTICLE
Qaid Ahmed Shagera, Ioannis Karfis, Spyridon Sideris, Thomas Guiot, Erwin Woff, Nieves Martinez-Chanza, Thierry Roumeguere, Thierry Gil, Patrick Flamen, Carlos Artigas
PURPOSE: The aim of this study was to evaluate the prognostic value of 68Ga-labeled prostate-specific membrane antigen (PSMA) PET/CT in metastatic castration-resistant prostate cancer patients receiving second-line chemotherapy with cabazitaxel. METHODS: All patients with metastatic castration-resistant prostate cancer who underwent a PSMA PET/CT within 8 weeks before initiating the cabazitaxel treatment were retrospectively evaluated. The whole-body PSMA total tumor volume (PSMA-TV) was measured for each patient...
June 29, 2023: Clinical Nuclear Medicine
https://read.qxmd.com/read/37378926/evaluation-of-second-primary-cancer-risk-among-chronic-lymphocytic-leukemia-patients-multicenter-study
#17
MULTICENTER STUDY
Selim Sayin, Emrah Kiliacslan, Murat Yildirim, Hacer Berna Afacan Ozturk, Esra Safak Yilmaz, Murat Albayrak, M Kursat Kaptan, Meltem Ayli
BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) have an increased risk of developing second primary cancers (SPC). The aim of this study is to determine the frequency of SPC in CLL patients and determine the relationship between these cancers and their treatment status, cytogenetic factors, and other risk factors. METHODS: The study was designed as multicenter and retroprospective. The sample comprised 553 subjects with a CLL diagnosis. Data collection commenced in August 2016, and completed at May 2021...
June 1, 2023: Asian Pacific Journal of Cancer Prevention: APJCP
https://read.qxmd.com/read/37370826/personalized-177lu-lutetium-psma-therapy-for-patients-with-pre-treated-castration-resistant-prostate-cancer-a-single-institution-experience-from-a-comprehensive-cancer-centre
#18
JOURNAL ARTICLE
Wolfgang Thaiss, Friedemann Zengerling, Julia Friedrich, Veronika Hechler, Michael Grunert, Christian Bolenz, Thomas Wiegel, Ambros J Beer, Vikas Prasad
Castration resistant prostate cancer (CRPC) is characterized by an aggressive biological behavior with a relatively short survival time, especially in progressive tumors pretreated with new hormonal agents and taxane chemotherapy. [177Lu]-Lutetium-PSMA (Lu-PSMA) treatment has proven efficacy in these patients. However, around 30% of the CRPC patients do not benefit from Lu-PSMA treatment, and little is known about predictive factors for treatment success if Lu-PSMA is offered in an individualized approach based on clinical and laboratory features...
June 16, 2023: Cancers
https://read.qxmd.com/read/37366458/a-case-of-hemorrhagic-myositis-associated-with-prophylactic-heparin-use-in-dermatomyositis
#19
Mery Bartl, Jose G Gomez Casanovas, Christine E Loftis, Laura Rincon-Rueda, Andres R Suarez Parraga
Dermatomyositis (DM) is a rare systemic autoimmune disease that is associated with inflammation of the skin and muscles. It typically presents with weakness of the proximal muscles along with characteristic skin lesions such as Gottron's papules and heliotrope rash. One of the most feared complications of this disease is the appearance of spontaneous hemorrhagic myositis, as most reported cases are fatal. The mechanism or risk factors of this condition have not been elucidated; however, prophylactic anticoagulation has been correlated with it in previous case reports, although idiopathic hemorrhagic myositis may also be present...
May 2023: Curēus
https://read.qxmd.com/read/37321824/safety-and-efficacy-of-177-lu-psma-i-t-radioligand-therapy-in-octogenarians-with-metastatic-castration-resistant-prostate-cancer-report-on-80-patients-over-the-age-of-80-years
#20
JOURNAL ARTICLE
Robert Tauber, Karina Knorr, Margitta Retz, Isabel Rauscher, Sonia Grigorascu, Kimberley Hansen, Calogero D'Alessandria, Hans-Jürgen Wester, Jürgen Gschwend, Wolfgang Weber, Matthias Eiber, Thomas Langbein
177 Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a new treatment option for metastatic castration-resistant prostate cancer (mCRPC). Its low toxicity profile favors use in elderly patients or in patients with critical comorbidities. The purpose of this analysis was to evaluate the efficacy and safety of [177 Lu]-PSMA RLT in mCRPC patients at least 80 y old. Methods: Eighty mCRPC patients at least 80 y old underwent [177 Lu]-PSMA-I&T RLT and were retrospectively selected...
June 15, 2023: Journal of Nuclear Medicine
keyword
keyword
79952
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.